EQS-News: Berlin Cures takes next step in battle against Long COVID
Retrieved on:
Tuesday, October 17, 2023
Berlin, Germany, 10 October 2023 – Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies (fAABs), is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.
Key Points:
- Berlin, Germany, 10 October 2023 – Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies (fAABs), is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.
- This partnership represents a significant step forward in the development of BC 007, Berlin Cures’ leading drug candidate for treating Long COVID and other autoimmune diseases.
- As an accredited research center for Long COVID, Uniklinikum Erlangen will help Berlin Cures compile significant data on the efficacy and safety of BC 007 for patients with Long COVID.
- Additionally, we are thrilled to be part of Berlin Cures' Phase II clinical trial, BLOC.”